Mar 29, 2011 11:07 ET
OPTIMIZERx Corporation Announces SampleMD Update
ROCHESTER, MI--(Marketwire - March 29, 2011) - OPTIMIZERx Corporation (OTCBB: OPRX) announced news relating to its 4Q 2010 launch of SampleMD -- its proprietary technology that provides physicians a more efficient alternative to storing drug samples by printing and electronically distributing prescription trial vouchers, co-pay coupons and other patient information right from their computers.
Pharmaceutical manufacturers contracted with SampleMD include Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Genentech Inc., Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc. and Warner Chilcott Company LLC.
Additionally, the Company is in various stages of contractual development with other leading pharmaceutical and biotech companies and is now leveraging its equity partner Physicians Interactive LLC to promote SampleMD through their highly established sales force.
The Company is very pleased by the number of blue chip companies who have recognized and signed up for SampleMD as a new way to reach more physicians at point of care. However, the company has recognized delays associated with extensive legal and compliance reviews that are commonly associated with innovative technology which provides new promotional processes. In response, the internal account team is working to streamline the approval process to fully ramp up promotional and revenue maximization.
Utilization of SampleMD within its initial rollout phase has already generated promotion and distribution of over 16,000 vouchers and co-pay coupons since its launch, with almost 5,000 in March alone and a redemption rate of 18% -- more than three times the industry average. We expect these numbers to dramatically escalate as we expand the number of participating brand manufacturers and fully ramp up our network of participating prescribers and health systems.
SampleMD's integration within Allscripts, the nation's largest ePrescribing provider, EMR platforms provides access to over 100,000 providers, right at point of ePrescribing, in addition to our leading health systems like Emory, Carilion, St. Barnabas and Ochsner whom are using SampleMD as their exclusive alternative to traditional drug samples.
The Company is also pursuing integration within other ePrescribing and Electronic Health Records enterprise companies who can provide an even larger base of healthcare providers.
The company's goal is to become the standard in delivering patient savings and support right at the most critical time: when the doctor is prescribing.
"With almost 200 million prescriptions electronically prescribed this year -- and that number is expecting to double in each of the next few years -- integration of SampleMD's eVouchers and promotional services will provide us the potential for huge growth," added David Harrell, Chairman and Founder of OptimizeRx, "We have proven SampleMD's ability to help the manufacturer increase product utilization while enabling doctors to help their patients better afford and stay on the medicines they need."
For more information about SampleMD, please go to www.samplemd.com.
About OPTIMIZERx Corporation
OPTIMIZERx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. For more information, please go to www.optimizerxcorp.com.
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Company contact:
Dave Lester
CEO
Optimizerx Corporation Inc.
248-651-6568
OPTIMIZERx Corporation Announces SampleMD Update
ROCHESTER, MI--(Marketwire - March 29, 2011) - OPTIMIZERx Corporation (OTCBB: OPRX) announced news relating to its 4Q 2010 launch of SampleMD -- its proprietary technology that provides physicians a more efficient alternative to storing drug samples by printing and electronically distributing prescription trial vouchers, co-pay coupons and other patient information right from their computers.
Pharmaceutical manufacturers contracted with SampleMD include Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Genentech Inc., Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc. and Warner Chilcott Company LLC.
Additionally, the Company is in various stages of contractual development with other leading pharmaceutical and biotech companies and is now leveraging its equity partner Physicians Interactive LLC to promote SampleMD through their highly established sales force.
The Company is very pleased by the number of blue chip companies who have recognized and signed up for SampleMD as a new way to reach more physicians at point of care. However, the company has recognized delays associated with extensive legal and compliance reviews that are commonly associated with innovative technology which provides new promotional processes. In response, the internal account team is working to streamline the approval process to fully ramp up promotional and revenue maximization.
Utilization of SampleMD within its initial rollout phase has already generated promotion and distribution of over 16,000 vouchers and co-pay coupons since its launch, with almost 5,000 in March alone and a redemption rate of 18% -- more than three times the industry average. We expect these numbers to dramatically escalate as we expand the number of participating brand manufacturers and fully ramp up our network of participating prescribers and health systems.
SampleMD's integration within Allscripts, the nation's largest ePrescribing provider, EMR platforms provides access to over 100,000 providers, right at point of ePrescribing, in addition to our leading health systems like Emory, Carilion, St. Barnabas and Ochsner whom are using SampleMD as their exclusive alternative to traditional drug samples.
The Company is also pursuing integration within other ePrescribing and Electronic Health Records enterprise companies who can provide an even larger base of healthcare providers.
The company's goal is to become the standard in delivering patient savings and support right at the most critical time: when the doctor is prescribing.
"With almost 200 million prescriptions electronically prescribed this year -- and that number is expecting to double in each of the next few years -- integration of SampleMD's eVouchers and promotional services will provide us the potential for huge growth," added David Harrell, Chairman and Founder of OptimizeRx, "We have proven SampleMD's ability to help the manufacturer increase product utilization while enabling doctors to help their patients better afford and stay on the medicines they need."
For more information about SampleMD, please go to www.samplemd.com.
About OPTIMIZERx Corporation
OPTIMIZERx Corp. provides unique consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. For more information, please go to www.optimizerxcorp.com.
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Company contact:
Dave Lester
CEO
Optimizerx Corporation Inc.
248-651-6568